Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future
Clonal haematopoiesis (CH) refers to the clonal expansion of haematopoietic stem cells in the absence of overt haematological malignancy and is common in older individuals. Recent evidence has heralded CH as a novel determinant of cardiovascular disease. This review explores the associations of CH with ischaemic heart disease, heart failure, atrial fibrillation and cardio-oncology, highlighting biases in the literature, exploring effects of mutation and clone size, concluding with clinical implications.
Authors
- Zahra Raisi‐Estabragh (ORCID: https://orcid.org/0000-0002-7757-5465)
- Rupen Hargreaves
- Dorina-Gabriela Condurache (ORCID: https://orcid.org/0000-0003-3985-0814)
- M. L. Anderson
- Sean Wen
- Paul Carter
- Alec P. Morley
Institutions
- AstraZeneca (United Kingdom) (GB)
- Queen Mary University of London (GB)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Barts Health NHS Trust (GB)
- University of Cambridge (GB)
- Manchester Academic Health Science Centre (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- University of Oxford (GB)
- MRC Weatherall Institute of Molecular Medicine (GB)
- London School of Economics and Political Science (GB)
Publication Details
- Journal
- npj Cardiovascular Health
- Published
- 2026-05-21
- DOI
- https://doi.org/10.1038/s44325-026-00127-4
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Barts Charity
- National Institute for Health and Care Research